ORIC-101,99.30%
产品编号:Bellancom-112710| CAS NO:2222344-98-9| 分子式:C34H47NO2| 分子量:501.74
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
ORIC-101
| 产品介绍 | ORIC-101 是一种有效、选择性的糖皮质激素受体 (glucocorticoid receptor) 拮抗剂,EC50 值为 5.6 nM。抗癌作用。 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | ORIC-101 is a highly potent and selective glucocorticoid receptor antagonist, with an EC50 of 5.6 nM. Anti-cancer activity. | ||||||||||||||||
| 体外研究 |
ORIC-101 shows markedly reduced androgen receptor agonism (EC50, 2500 nM) and CYP2C8 and CYP2C9 inhibition profiles (IC50, >10 μM). 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 体内研究 |
ORIC-101 (75 mg/kg, P.O. twice a day for 16-22 days) enhances the anti-tumor activity in combination with gemcitabine and carboplatin in OVCAR5 xenograft tumor in cortisol-treated mice. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
| 体内研究 |
ORIC-101 (75 mg/kg, P.O. twice a day for 16-22 days) enhances the anti-tumor activity in combination with gemcitabine and carboplatin in OVCAR5 xenograft tumor in cortisol-treated mice. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : ≥ 100 mg/mL (199.31 mM) * "≥" means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 参考文献 |

浙公网安备 33010802013016号